XBiotech is leading the development of next generation biological therapies and production systems. The Company has a rich pipeline of first-in-class True Human™ antibodies—a better, safer platform from which to produce therapeutic antibodies. XBiotech is also dramatically reducing the capital footprint to bring biological therapies to market—with new technology that collapses the complex, capital intensive infrastructure of biological manufacturing. In the end, our efforts are aimed at delivering safe, well tolerated breakthrough therapies with better value for patients and shareholders alike.